Sep 14, 2017
BEVERLY, MA --(Marketwired - September 14, 2017) - In the news release, "First Patent Enrolled in BioVie Phase 2a Clinical Trial of BIV201 for Ascites," issued earlier today by BioVie Inc. (OTCQB: BIVI), we are advised by the company that the title of the release should read "First Patient Enrolled ...
Sep 14, 2017
BEVERLY, MA--(Marketwired - September 14, 2017) - BioVie Inc. (OTCQB: BIVI), a clinical-stage company focused on the discovery, development, and commercialization of innovative drug therapies for liver disease, today confirmed enrollment of the first patient in the Company's mid-stage (Phase 2a) cl...
Aug 29, 2017
BEVERLY, MA--(Marketwired - August 29, 2017) - BioVie Inc. (OTCQB: BIVI), a clinical-stage company focused on the discovery, development, and commercialization of innovative drug therapies for liver disease, today reported financial results for the fiscal year ended June 30, 2017, and summarized the...